Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
29
06
2023
accepted:
08
12
2023
revised:
26
10
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of transformation into myelofibrosis or acute myeloid leukemia (AML) and TP53 mutations in MPN patients are linked to AML. However, JAK2V617F has been reported to impact the TP53 response to DNA damage, suggesting potential overlapping role of TP53 inactivation in MPN. We established a mouse model showing that JAK2V617F/Vav-Cre/Trp53
Identifiants
pubmed: 38177095
doi: 10.1038/s41408-023-00969-6
pii: 10.1038/s41408-023-00969-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Campbell PeterJ. ARG. The myeloproliferative disorders. N Engl J Med. 2006;355:2452–66.
doi: 10.1056/NEJMra063728
pubmed: 17151367
Ugo V, James C, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
doi: 10.1038/nature03546
pubmed: 15793561
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.
doi: 10.1056/NEJMoa051113
pubmed: 15858187
Baxter EJoanna, Scott LindaM, Campbell PeterJ, East Clare, Fourouclas Nasios, Swanton Soheila, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.
doi: 10.1016/S0140-6736(05)71142-9
pubmed: 15781101
Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788–92.
doi: 10.1074/jbc.C500138200
pubmed: 15863514
Levine RossL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.
doi: 10.1016/j.ccr.2005.03.023
pubmed: 15837627
Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31:1323–33.
doi: 10.1038/onc.2011.313
pubmed: 21785463
Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124:771–9.
doi: 10.1182/blood-2013-11-536854
pubmed: 24869939
pmcid: 4467881
Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120:3098–105.
doi: 10.1182/blood-2012-02-410712
pubmed: 22872685
pmcid: 3471518
Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012;26:1037–51.
doi: 10.1016/j.hoc.2012.07.005
pubmed: 23009936
Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85:124–7.
doi: 10.1159/000204873
pubmed: 2042444
Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364:488–90.
doi: 10.1056/NEJMc1012718
pubmed: 21288114
Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416–30.
doi: 10.1056/NEJMoa1716614
pubmed: 30304655
pmcid: 7030948
Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123:2075–83.
doi: 10.1182/blood-2014-01-547760
pubmed: 24470592
pmcid: 3968390
Tsuruta-Kishino T, et al. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. Oncogene. 2017;36:3300–11.
doi: 10.1038/onc.2016.478
pubmed: 28068330
Li B, An W, Wang H, Baslan T, Mowla S, Krishnan A, et al. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood. 2022;139:3630–46.
doi: 10.1182/blood.2021014465
pubmed: 35421216
pmcid: 9728578
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–9.
doi: 10.1038/348747a0
pubmed: 2259385
Molica M, Mazzone C, Niscola P, de Fabritiis P. TP53 mutations in acute myeloid leukemia: still a daunting challenge? Front Oncol. 2021;10:610820.
doi: 10.3389/fonc.2020.610820
pubmed: 33628731
pmcid: 7897660
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–8.
doi: 10.1182/blood-2013-11-537167
pubmed: 24478400
Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891–900.
doi: 10.1182/blood-2009-08-236596
pubmed: 20008300
Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018;32:450–61.
doi: 10.1038/leu.2017.230
pubmed: 28744014
Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016;9:89–95.
doi: 10.1016/j.hemonc.2016.04.003
pubmed: 27187622
Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood [Internet]. 2013;122:1464–77. https://doi.org/10.1182/blood-2013-04-498956 .
doi: 10.1182/blood-2013-04-498956
pubmed: 23863895
Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91:419–30.
doi: 10.1182/blood.V91.2.419
pubmed: 9427694
Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94:1855–63.
doi: 10.1182/blood.V94.6.1855
pubmed: 10477714
Shimshek DR, et al. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis. 2002;32:19–26.
doi: 10.1002/gene.10023
pubmed: 11835670
Learning M, Cookbook R. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–21.
doi: 10.1038/356215a0
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O’Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55:1531–41.
doi: 10.1038/s41588-023-01480-1
pubmed: 37666991
pmcid: 10484789
Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121:3692–702.
doi: 10.1182/blood-2012-05-432989
pubmed: 23487027
pmcid: 3643767
Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, et al. Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7:e2560.
doi: 10.1038/cddis.2016.430
pubmed: 28005077
pmcid: 5260985
Girardot M, Pecquet C, Chachoua I, van Hees J, Guibert S, Ferrant A, et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2015;34:1323–32.
doi: 10.1038/onc.2014.60
pubmed: 24681953
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996;272:719–22.
doi: 10.1126/science.272.5262.719
pubmed: 8614832
Stephanou A, Latchman DS. STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003;84:239–44.
doi: 10.1111/j.0959-9673.2003.00363.x
pubmed: 14748743
pmcid: 2517573
Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037–40.
doi: 10.1182/blood-2006-03-009860
pubmed: 16709929
Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–81.
doi: 10.1038/leu.2015.326
pubmed: 26601783